期刊文献+

组蛋白去乙酰化酶3在急性白血病细胞株中的表达 被引量:2

Expression of histone deacetylase 3 in acute leukemic cell lines
下载PDF
导出
摘要 目的:研究组蛋白去乙酰化酶3(histone deacetylase 3,HDAC3)在不同类型急性白血病细胞株中的表达,观察HDAC3表达和细胞分化增殖的关系。方法:在16株白血病细胞株中采用实时定量PCR法及Western印迹法检测HDAC3的mRNA及蛋白质表达,检测NB4细胞株在维甲酸诱导分化过程中HDAC3 mRNA及蛋白质表达变化情况。结果:在NB4、NB4RA和NOMO-1细胞株中HDAC3 mRNA表达量较高,但蛋白质的表达与此不一致。在维甲酸诱导的NB4细胞分化过程中HDAC3 mRNA和蛋白质的表达呈下降趋势。结论:HDAC3的表达是白血病细胞生长所必须,在NB4细胞中HDAC3表达和细胞的分化和增殖状态相关。 Objective :To study the expression of histone deacetylase 3 (HDAC3) in acute leukemic cell lines and to observe whether the HDAC3 expression is necessary for the transcriptional regulation by controlling proliferation and differentiation of leukemia cells. Methods:The HDAC3 mRNA and protein expression levels in 16 acute myeloid leukemic cell lines were assessed by real-time quantitative PCR (RTQ-PCR) and Western blotting, respectively. The mRNA and protein expression levels of HDAC3 were detected during differentiation of NB4 cells induced by all-trans retinoic acid (ATRA). Results:The mRNA expressions of HDAC3 were higher in NB4, NB4RA and NOMO-1 leukemic cell lines but the protein expression levels were not parallel with mRNA expressions. HDAC3 mRNA and protein expression had a decreased tendency during the ATRA-induced differentiation of NB4 cells. Conclusion : HDAC3 is necessary for proliferation of leukemic cells and the expression of HDAC3 in NB4 cell line is associated with cell differentiation and/or proliferation.
出处 《肿瘤》 CAS CSCD 北大核心 2008年第4期313-316,共4页 Tumor
关键词 组蛋白脱乙酰化酶类 维甲酸 白血病 非淋巴细胞 急性 Histone deacetylases Tretinoin Leukemia , myelocytic, acute
  • 相关文献

参考文献14

  • 1MOE-BEHRENS G H, PANDOLFI P P. Targeting aberrant transcriptional repression in acute leukemia[ J]. Rev Clin Exp Hematol, 2003,7(2) :139-159.
  • 2FU M, WANG C, ZHANG X, et al. Acetylation of nuclear receptors in cellular growth and apoptosis[ J ]. Biochemi Pharm, 2004, 68(6) : 1199-1208.
  • 3BRADBURY C A, KHANIM F L, HAYDEN R, et al. Histone deacetylases in acute myeloid leukemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors[ J]. Leukemia, 2005,19(10) : 1751-1759.
  • 4DRUMMOND D C, NOBLE C O, KIRPOTIN D B, et al. Clinical development of histone deacetylase inhibitors as anticancer agents [ J]. Annu Rev Pharmacol Toxicol, 2005,45:495-528.
  • 5BHALLA K,LIST A. Histone deacetylase inhibitors in myelodysplastic syndrome [ J]. Best Pract Res Clin Haematol, 2004, 17 (4) :595-611.
  • 6ISHIZUKA T, LAZAR M A. The N-CoR-histone deacetylase 3 complex is required for repression by thyroid hormone receptor [ J ]. Mol Cell Biol, 2003 ;23(15) :5122-5131.
  • 7LI J, WANG J, WANG JX, et al. Both corepresor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3 [ J ]. EMBO,2005,19 (16) :4342-4350.
  • 8HUANG ME, YE YC, CHEN SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia[ J ]. Blood, 1988,72 (2) :567-572.
  • 9WALTREGNY D, NORTH B, Van MELLAERT F, et al. Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class Ⅰ HDAC profiles between epithelial and stromal cells [ J ]. Eur J Histochem, 2004,48 ( 3 ) :273-290.
  • 10DREXLER H G, QUENTMEIEr H, MacLEOD R A. Malignant hematopoietic cell lines, in vitro models for the study of MLL gene alterations[J]. Leukemia, 2004,18(2) :227-232.

同被引文献19

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部